Neuromuscular transmission & factors modifying block . Simple and exam ready format . In a way I can remember and reproduce for md anaesthesia exam

Reading File

Finding Sources

Searching PubMed

neuromuscular blockade AND anesthesia

Searching the Web

neuromuscular blocking drugs factors modifying block anaesthesia review

Reading File

Finding Sources

Neuromuscular transmission and factors modifying neuromuscular block

1. Neuromuscular junction: a 30-second introduction

Neuromuscular transmission is conversion of a nerve action potential into skeletal-muscle contraction at the motor end plate.

Diagram to reproduce

Motor nerve terminal        Synaptic cleft             Muscle end plate
      ↓                          ↓                            ↓
AP arrives → Ca2+ influx → ACh release → ACh binds Nm receptor
                                                        ↓
                                              Na+ in, K+ out
                                                        ↓
                                            End-plate potential
                                                        ↓
                                           Muscle action potential
                                                        ↓
                                               Ca2+ release from SR
                                                        ↓
                                                 Contraction

Sequence: “A-C-A-R-E-C”

Action potential reaches presynaptic motor-nerve terminal.
Voltage-gated Calcium channels open and Ca²⁺ enters the nerve terminal.
ACh vesicles fuse with presynaptic membrane and release ACh quanta.
ACh binds to both alpha subunits of postjunctional Recptor, the nicotinic muscle receptor, Nm.
Ion channel opens, producing End-plate potential:
- Na⁺ and Ca²⁺ enter
- K⁺ leaves
Muscle action potential causes SR Ca²⁺ release and contraction.

ACh is rapidly hydrolysed by acetylcholinesterase into acetate and choline. Choline is reuptaken into the nerve terminal for ACh resynthesis.

The adult Nm receptor is a pentamer: 2α, β, δ, ε. Both alpha subunits must bind ACh before the channel opens. At the normal NMJ, only about 10% of receptors need activation for contraction, producing a large margin of safety.
Morgan and Mikhail's Clinical Anesthesiology, 7e, pp. 369-371.

2. Mechanism of neuromuscular block

Drug group	Receptor action	Pattern on nerve stimulation
Depolarising: succinylcholine	Nm agonist. Persistent end-plate depolarisation prevents repolarisation	Phase I: no fade, no post-tetanic facilitation
Nondepolarising: rocuronium, vecuronium, atracurium, cisatracurium	Competitive Nm antagonists. Prevent ACh binding and channel opening	Fade on TOF and tetanus; post-tetanic facilitation

Why does fade occur with nondepolarising block?

Nondepolarising drugs also block presynaptic nicotinic receptors, decreasing mobilisation and release of ACh during repeated stimulation. Thus each successive twitch becomes weaker.

Phase II block with succinylcholine

Occurs after large doses, repeated doses, or prolonged infusion.

It resembles a nondepolarising block:

TOF fade appears
Post-tetanic facilitation appears
Mechanism includes receptor desensitisation and altered membrane behaviour

3. Factors modifying neuromuscular block

Best exam classification: “Patient - Physiology - Drugs - Technique”

A. Patient factors

Factor	Effect on block	Explanation / exam point
Age: neonates/infants	Variable, often prolonged clinically	Immature NMJ, altered volume of distribution and organ function
Elderly	Prolonged, especially aminosteroids	Reduced cardiac output, renal function and hepatic blood flow
Obesity	Risk of relative overdose if dosed on total body weight	Dose according to agent-specific weight scalar
Myasthenia gravis	Markedly sensitive to nondepolarising drugs	Fewer functional postjunctional ACh receptors
Lambert-Eaton syndrome	Markedly sensitive to both drug classes	Reduced presynaptic ACh release
Motor neuron disease / neuropathy / critical illness myopathy	Variable and often increased sensitivity to nondepolarisers	Reduced muscle mass and altered receptors
Burns, denervation, immobilisation, upper motor neuron lesions	Resistance to nondepolarisers; dangerous hyperkalaemia with succinylcholine	Upregulation of extrajunctional ACh receptors
Renal failure	Prolonged block with renally excreted agents	Particularly pancuronium, vecuronium and rocuronium
Hepatic failure	Prolonged aminosteroid block	Reduced biliary elimination and altered distribution
Low cardiac output / shock	Delayed onset but prolonged duration	Reduced delivery to NMJ and reduced clearance

High-yield disease rule

Fewer receptors or less ACh release = more sensitivity to nondepolarising block.
More extrajunctional receptors = resistance to nondepolarisers, but risk with succinylcholine.

B. Physiological and metabolic factors

Factors that potentiate nondepolarising block

Mnemonic: “Cold, Acid, Low salts, High Mg”

Factor	Effect / mechanism
Hypothermia	Prolongs block: reduces ACh mobilisation, muscle contraction, hepatic and renal metabolism, and Hofmann degradation
Respiratory or metabolic acidosis / hypercarbia	Potentiates block
Hypokalaemia	Potentiates block and makes neostigmine reversal less effective
Hypocalcaemia	Potentiates block due to reduced ACh release
Hypermagnesaemia	Strong potentiation: reduced presynaptic Ca²⁺-dependent ACh release plus postsynaptic effects
Hyponatraemia	May increase block
Hypophosphataemia	Muscle weakness, may worsen clinical recovery

Hypothermia also makes peripheral nerve monitoring misleading if the monitored arm is cold.
Barash, Cullen, and Stoelting’s Clinical Anesthesia, 9e, pp. 1434-1443.

Factors that may antagonise nondepolarising block

Hypercalcaemia
Hyperkalaemia, generally
Alkalosis, although clinical effects can be inconsistent
Chronic anticonvulsant therapy
Burns, denervation and prolonged immobilisation, through receptor upregulation

C. Drug interactions

1. Anaesthetic drugs

Drug / technique	Effect
Volatile anaesthetics	Potentiate and prolong nondepolarising block
Order of potentiation	Desflurane > sevoflurane > isoflurane > halothane > N₂O / opioid / propofol anaesthesia
Propofol	Minimal effect on duration of block
Local anaesthetics	Can potentiate block, particularly at high systemic concentrations
Ketamine, opioids, benzodiazepines	No major direct NMJ action at usual doses, but may worsen apparent weakness through central respiratory depression

Volatile anaesthetics reduce dose requirements and prolong recovery from nondepolarising NMBAs. The effect is greater with higher concentration and longer exposure.
Miller's Anesthesia, 10e, p. 3306-3307.

2. Antibiotics

Mnemonic: “A P C T block ACh”

Aminoglycosides: gentamicin, amikacin, tobramycin, neomycin
Polymyxins
Clindamycin and lincomycin
Tetracyclines

Mechanism: mainly reduced presynaptic ACh release. Aminoglycosides, polymyxins, clindamycin and lincomycin additionally reduce postsynaptic receptor sensitivity.

Clinical point: aminoglycosides can cause weakness even without an NMBA and may make neostigmine reversal difficult.
Miller's Anesthesia, 10e, p. 3308.

3. Other drugs potentiating nondepolarising block

Magnesium sulfate
Lithium
Calcium-channel blockers, especially verapamil
Antiarrhythmics: quinidine, procainamide, disopyramide
Diuretics, indirectly through hypokalaemia and hypomagnesaemia
High-dose corticosteroids, especially in critically ill patients receiving prolonged NMBA
Acute phenytoin or carbamazepine therapy

4. Drugs causing resistance or shortening block

Chronic phenytoin or carbamazepine therapy
- Resistance and shortened duration, especially with aminosteroid NMBAs
- Mechanisms include enzyme induction and receptor changes
Theophylline
Calcium
Anticholinesterases, if given before the NMBA

5. Interaction between muscle relaxants

Combining two nondepolarising NMBAs may be additive or synergistic. Avoid routine mixing.
A defasciculating dose of a nondepolarising drug antagonises succinylcholine Phase I block, so a larger succinylcholine dose may be required.
Prior succinylcholine may sometimes potentiate the later nondepolarising block, but evidence is inconsistent.

D. Factors modifying succinylcholine block specifically

Prolonged succinylcholine action

Mnemonic: “Low enzyme or enzyme inhibition”

Inherited atypical butyrylcholinesterase
Low butyrylcholinesterase states
- Pregnancy and early postpartum period
- Liver disease
- Malnutrition
- Severe burns
- Malignancy
- Chronic renal disease
- Organophosphate exposure
Drugs that inhibit butyrylcholinesterase
- Anticholinesterases
- Echothiophate eye drops
- Organophosphates
- Metoclopramide
- Some local anaesthetics, especially procaine
Hypothermia

Resistance to succinylcholine

Burns
Denervation
Severe infection or trauma
Chronic immobilisation
Muscular dystrophies and receptor upregulation states

However, in these receptor-upregulation states, succinylcholine can cause life-threatening hyperkalaemia and is usually avoided.

4. A concise 10-mark answer to reproduce

Factors potentiating nondepolarising neuromuscular block

1. Patient factors

Elderly age
Renal or hepatic dysfunction
Low cardiac output
Myasthenia gravis, Lambert-Eaton syndrome, neuromuscular diseases
Critical illness and muscle wasting

2. Metabolic factors

Hypothermia
Acidosis and hypercarbia
Hypokalaemia
Hypocalcaemia
Hypermagnesaemia

3. Drug interactions

Volatile anaesthetics: desflurane > sevoflurane > isoflurane
Aminoglycosides, polymyxins, clindamycin, tetracyclines
Magnesium
Lithium
Calcium-channel blockers
Quinidine and other antiarrhythmics
Local anaesthetics

4. Technique-related factors

Large or repeated NMBA doses
Combination of different nondepolarising drugs
Inadequate monitoring and failure to adjust dose

5. Clinical implication

Use quantitative neuromuscular monitoring.
Titrate further doses to monitoring rather than time alone.
Correct temperature and electrolyte disturbances.
Extubate only after adequate recovery, generally TOF ratio ≥0.9.

One-line memory aid

“Cold, acid, low K/Ca, high Mg, volatiles, antibiotics, weak patients, and failing liver/kidney make nondepolarising block deeper and longer.”

Final viva pearl

Neuromuscular blockers do not provide unconsciousness, amnesia, or analgesia. A paralysed patient can still be awake, so anaesthesia and analgesia must always be adequate.

This is a shared conversation. Sign in to Orris to start your own chat.